Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxVRCDF -60.53% Debt-to-Equity is 0.03 as of Dec. 2025, which is 50% below its 10-year median of 0.06. The stock has 3 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Verici Dx ranks better than 90.16% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Verici Dx's Debt-to-Equity or its related term are showing as below:
VRCDF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.06 Max: 0.15
Current: 0.03
During the past 6 years, the highest Debt-to-Equity Ratio of Verici Dx was 0.15. The lowest was 0.00. And the median was 0.06.
VRCDF's Debt-to-Equity is ranked better than 90.16% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.32
vs VRCDF: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Verici Dx Debt-to-Equity Related Terms
Verici Dx Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Verici Dx's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRCDF vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Verici Dx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Verici Dx's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (VRCDF) has a Debt-to-Equity of 0.03 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Verici Dx and its competitors. This is 50% below median its historical median of 0.06. According to the industry distribution chart, Verici Dx ranks #18 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 9.8%.
Is Verici Dx's Debt-to-Equity too high?
Verici Dx's current Debt-to-Equity of 0.03 is 50% below median its 10-year median of 0.06. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.32. Verici Dx's value of 0.03 is 90.6% below this industry median. Based on the distribution chart, Verici Dx ranks #18 out of 183 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #18 out of 183 companies for Debt-to-Equity. This places Verici Dx in the top 10% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.32. Verici Dx's value of 0.03 is 90.6% below this benchmark. While the company's 10-year median is 0.06 vs. the industry median of 0.32, Verici Dx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.32, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verici Dx's current Debt-to-Equity of 0.03 is 90.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current Debt-to-Equity is 0.03, which is 50% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current Debt-to-Equity of 0.03. The current Debt-to-Equity is 0.03, which is 50% below median its 10-year median of 0.06 and 90.6% below the Medical Diagnostics & Research industry median of 0.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Verici Dx (VRCDF), the current Debt-to-Equity is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
